Global Oral Hypoglycemic Drugs Market Growth 2020-2025

Publisher Name :
Date: 02-Jun-2020
No. of pages: 164

COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

According to this latest study, the 2020 growth of Oral Hypoglycemic Drugs will have significant change from previous year. By the most conservative estimates of global Oral Hypoglycemic Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Oral Hypoglycemic Drugs market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Hypoglycemic Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Oral Hypoglycemic Drugs, covering the supply chain analysis, impact assessment to the Oral Hypoglycemic Drugs market size growth rate in several scenarios, and the measures to be undertaken by Oral Hypoglycemic Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.

- Sulfonylureas (SU)

- Double Guanidine

- Glucosidase Inhibitor

- Insulin Synergist

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.

- Hospital

- Clinic

- Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

- Americas

- United States

- Canada

- Mexico

- Brazil

- APAC

- China

- Japan

- Korea

- Southeast Asia

- India

- Australia

- Europe

- Germany

- France

- UK

- Italy

- Russia

- Middle East & Africa

- Egypt

- South Africa

- Israel

- Turkey

- GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

- Pfizer

- Servier Laboratories

- AstraZeneca

- GlaxoSmithKline

- Merck & Co

- Johnson & Johnson

- Takeda Pharmaceuticals

- Eli Lilly

- Novo Nordisk

- Sanofi

- Boehringer Ingelheim

- Bristol-Myers Squibb

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

- To study and analyze the global Oral Hypoglycemic Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.

- To understand the structure of Oral Hypoglycemic Drugs market by identifying its various subsegments.

- Focuses on the key global Oral Hypoglycemic Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

- To analyze the Oral Hypoglycemic Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.

- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

- To project the consumption of Oral Hypoglycemic Drugs submarkets, with respect to key regions (along with their respective key countries).

- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

- To strategically profile the key players and comprehensively analyze their growth strategies.

Global Oral Hypoglycemic Drugs Market Growth 2020-2025

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Oral Hypoglycemic Drugs
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Oral Hypoglycemic Drugs Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral Hypoglycemic Drugs Consumption 2015-2025
2.1.2 Oral Hypoglycemic Drugs Consumption CAGR by Region
2.2 Oral Hypoglycemic Drugs Segment by Type
2.2.1 Sulfonylureas (SU)
2.2.2 Double Guanidine
2.2.3 Glucosidase Inhibitor
2.2.4 Insulin Synergist
2.3 Oral Hypoglycemic Drugs Consumption by Type
2.3.1 Global Oral Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Oral Hypoglycemic Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Oral Hypoglycemic Drugs Sale Price by Type (2015-2020)
2.4 Oral Hypoglycemic Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Oral Hypoglycemic Drugs Consumption by Application
2.5.1 Global Oral Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Oral Hypoglycemic Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Oral Hypoglycemic Drugs Sale Price by Type (2015-2020)

3 Global Oral Hypoglycemic Drugs by Company
3.1 Global Oral Hypoglycemic Drugs Sales Market Share by Company
3.1.1 Global Oral Hypoglycemic Drugs Sales by Company (2018-2020)
3.1.2 Global Oral Hypoglycemic Drugs Sales Market Share by Company (2018-2020)
3.2 Global Oral Hypoglycemic Drugs Revenue Market Share by Company
3.2.1 Global Oral Hypoglycemic Drugs Revenue by Company (2018-2020)
3.2.2 Global Oral Hypoglycemic Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Oral Hypoglycemic Drugs Sale Price by Company
3.4 Global Oral Hypoglycemic Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Oral Hypoglycemic Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Oral Hypoglycemic Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Oral Hypoglycemic Drugs by Regions
4.1 Oral Hypoglycemic Drugs by Regions
4.2 Americas Oral Hypoglycemic Drugs Consumption Growth
4.3 APAC Oral Hypoglycemic Drugs Consumption Growth
4.4 Europe Oral Hypoglycemic Drugs Consumption Growth
4.5 Middle East & Africa Oral Hypoglycemic Drugs Consumption Growth

5 Americas
5.1 Americas Oral Hypoglycemic Drugs Consumption by Countries
5.1.1 Americas Oral Hypoglycemic Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Oral Hypoglycemic Drugs Value by Countries (2015-2020)
5.2 Americas Oral Hypoglycemic Drugs Consumption by Type
5.3 Americas Oral Hypoglycemic Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Oral Hypoglycemic Drugs Consumption by Regions
6.1.1 APAC Oral Hypoglycemic Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Oral Hypoglycemic Drugs Value by Regions (2015-2020)
6.2 APAC Oral Hypoglycemic Drugs Consumption by Type
6.3 APAC Oral Hypoglycemic Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Oral Hypoglycemic Drugs by Countries
7.1.1 Europe Oral Hypoglycemic Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Oral Hypoglycemic Drugs Value by Countries (2015-2020)
7.2 Europe Oral Hypoglycemic Drugs Consumption by Type
7.3 Europe Oral Hypoglycemic Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Oral Hypoglycemic Drugs by Countries
8.1.1 Middle East & Africa Oral Hypoglycemic Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Oral Hypoglycemic Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Oral Hypoglycemic Drugs Consumption by Type
8.3 Middle East & Africa Oral Hypoglycemic Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Oral Hypoglycemic Drugs Distributors
10.3 Oral Hypoglycemic Drugs Customer

11 Global Oral Hypoglycemic Drugs Market Forecast
11.1 Global Oral Hypoglycemic Drugs Consumption Forecast (2021-2025)
11.2 Global Oral Hypoglycemic Drugs Forecast by Regions
11.2.1 Global Oral Hypoglycemic Drugs Forecast by Regions (2021-2025)
11.2.2 Global Oral Hypoglycemic Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Oral Hypoglycemic Drugs Forecast by Type
11.8 Global Oral Hypoglycemic Drugs Forecast by Application

12 Key Players Analysis
12.1 Pfizer
12.1.1 Company Information
12.1.2 Oral Hypoglycemic Drugs Product Offered
12.1.3 Pfizer Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Pfizer Latest Developments
12.2 Servier Laboratories
12.2.1 Company Information
12.2.2 Oral Hypoglycemic Drugs Product Offered
12.2.3 Servier Laboratories Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Servier Laboratories Latest Developments
12.3 AstraZeneca
12.3.1 Company Information
12.3.2 Oral Hypoglycemic Drugs Product Offered
12.3.3 AstraZeneca Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 AstraZeneca Latest Developments
12.4 GlaxoSmithKline
12.4.1 Company Information
12.4.2 Oral Hypoglycemic Drugs Product Offered
12.4.3 GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 GlaxoSmithKline Latest Developments
12.5 Merck & Co
12.5.1 Company Information
12.5.2 Oral Hypoglycemic Drugs Product Offered
12.5.3 Merck & Co Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Merck & Co Latest Developments
12.6 Johnson & Johnson
12.6.1 Company Information
12.6.2 Oral Hypoglycemic Drugs Product Offered
12.6.3 Johnson & Johnson Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Johnson & Johnson Latest Developments
12.7 Takeda Pharmaceuticals
12.7.1 Company Information
12.7.2 Oral Hypoglycemic Drugs Product Offered
12.7.3 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Takeda Pharmaceuticals Latest Developments
12.8 Eli Lilly
12.8.1 Company Information
12.8.2 Oral Hypoglycemic Drugs Product Offered
12.8.3 Eli Lilly Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Eli Lilly Latest Developments
12.9 Novo Nordisk
12.9.1 Company Information
12.9.2 Oral Hypoglycemic Drugs Product Offered
12.9.3 Novo Nordisk Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Novo Nordisk Latest Developments
12.10 Sanofi
12.10.1 Company Information
12.10.2 Oral Hypoglycemic Drugs Product Offered
12.10.3 Sanofi Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Sanofi Latest Developments
12.11 Boehringer Ingelheim
12.11.1 Company Information
12.11.2 Oral Hypoglycemic Drugs Product Offered
12.11.3 Boehringer Ingelheim Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Boehringer Ingelheim Latest Developments
12.12 Bristol-Myers Squibb
12.12.1 Company Information
12.12.2 Oral Hypoglycemic Drugs Product Offered
12.12.3 Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Bristol-Myers Squibb Latest Developments

13 Research Findings and Conclusion

List of Tables

Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Oral Hypoglycemic Drugs Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Oral Hypoglycemic Drugs Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Oral Hypoglycemic Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Sulfonylureas (SU)
Table 7. Major Players of Double Guanidine
Table 8. Major Players of Glucosidase Inhibitor
Table 9. Major Players of Insulin Synergist
Table 10. Global Consumption Sales by Type (2015-2020)
Table 11. Global Oral Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 12. Global Oral Hypoglycemic Drugs Revenue by Type (2015-2020) ($ million)
Table 13. Global Oral Hypoglycemic Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 14. Global Oral Hypoglycemic Drugs Sale Price by Type (2015-2020)
Table 15. Global Consumption Sales by Application (2015-2020)
Table 16. Global Oral Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 17. Global Oral Hypoglycemic Drugs Value by Application (2015-2020)
Table 18. Global Oral Hypoglycemic Drugs Value Market Share by Application (2015-2020)
Table 19. Global Oral Hypoglycemic Drugs Sale Price by Application (2015-2020)
Table 20. Global Oral Hypoglycemic Drugs Sales by Company (2017-2019) (K Units)
Table 21. Global Oral Hypoglycemic Drugs Sales Market Share by Company (2017-2019)
Table 22. Global Oral Hypoglycemic Drugs Revenue by Company (2017-2019) ($ Millions)
Table 23. Global Oral Hypoglycemic Drugs Revenue Market Share by Company (2017-2019)
Table 24. Global Oral Hypoglycemic Drugs Sale Price by Company (2017-2019)
Table 25. Global Oral Hypoglycemic Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 26. Players Oral Hypoglycemic Drugs Products Offered
Table 27. Oral Hypoglycemic Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 28. Global Oral Hypoglycemic Drugs Consumption by Regions 2015-2020 (K Units)
Table 29. Global Oral Hypoglycemic Drugs Consumption Market Share by Regions 2015-2020
Table 30. Global Oral Hypoglycemic Drugs Value by Regions 2015-2020 ($ Millions)
Table 31. Global Oral Hypoglycemic Drugs Value Market Share by Regions 2015-2020
Table 32. Americas Oral Hypoglycemic Drugs Consumption by Countries (2015-2020) (K Units)
Table 33. Americas Oral Hypoglycemic Drugs Consumption Market Share by Countries (2015-2020)
Table 34. Americas Oral Hypoglycemic Drugs Value by Countries (2015-2020) ($ Millions)
Table 35. Americas Oral Hypoglycemic Drugs Value Market Share by Countries (2015-2020)
Table 36. Americas Oral Hypoglycemic Drugs Consumption by Type (2015-2020) (K Units)
Table 37. Americas Oral Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 38. Americas Oral Hypoglycemic Drugs Consumption by Application (2015-2020) (K Units)
Table 39. Americas Oral Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 40. APAC Oral Hypoglycemic Drugs Consumption by Countries (2015-2020) (K Units)
Table 41. APAC Oral Hypoglycemic Drugs Consumption Market Share by Countries (2015-2020)
Table 42. APAC Oral Hypoglycemic Drugs Value by Regions (2015-2020) ($ Millions)
Table 43. APAC Oral Hypoglycemic Drugs Value Market Share by Regions (2015-2020)
Table 44. APAC Oral Hypoglycemic Drugs Consumption by Type (2015-2020) (K Units)
Table 45. APAC Oral Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 46. APAC Oral Hypoglycemic Drugs Consumption by Application (2015-2020) (K Units)
Table 47. APAC Oral Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 48. Europe Oral Hypoglycemic Drugs Consumption by Countries (2015-2020) (K Units)
Table 49. Europe Oral Hypoglycemic Drugs Consumption Market Share by Countries (2015-2020)
Table 50. Europe Oral Hypoglycemic Drugs Value by Countries (2015-2020) ($ Millions)
Table 51. Europe Oral Hypoglycemic Drugs Value Market Share by Countries (2015-2020)
Table 52. Europe Oral Hypoglycemic Drugs Consumption by Type (2015-2020) (K Units)
Table 53. Europe Oral Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 54. Europe Oral Hypoglycemic Drugs Consumption by Application (2015-2020) (K Units)
Table 55. Europe Oral Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 56. Middle East & Africa Oral Hypoglycemic Drugs Consumption by Countries (2015-2020) (K Units)
Table 57. Middle East & Africa Oral Hypoglycemic Drugs Consumption Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Oral Hypoglycemic Drugs Value by Countries (2015-2020) ($ Millions)
Table 59. Middle East & Africa Oral Hypoglycemic Drugs Value Market Share by Countries (2015-2020)
Table 60. Middle East & Africa Oral Hypoglycemic Drugs Consumption by Type (2015-2020) (K Units)
Table 61. Middle East & Africa Oral Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 62. Middle East & Africa Oral Hypoglycemic Drugs Consumption by Application (2015-2020) (K Units)
Table 63. Middle East & Africa Oral Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 64. Oral Hypoglycemic Drugs Distributors List
Table 65. Oral Hypoglycemic Drugs Customer List
Table 66. Global Oral Hypoglycemic Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 67. Global Oral Hypoglycemic Drugs Consumption Market Forecast by Regions
Table 68. Global Oral Hypoglycemic Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 69. Global Oral Hypoglycemic Drugs Value Market Share Forecast by Regions
Table 70. Global Oral Hypoglycemic Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 71. Global Oral Hypoglycemic Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 72. Global Oral Hypoglycemic Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 73. Global Oral Hypoglycemic Drugs Value Market Share Forecast by Type (2021-2025)
Table 74. Global Oral Hypoglycemic Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 75. Global Oral Hypoglycemic Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 76. Global Oral Hypoglycemic Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 77. Global Oral Hypoglycemic Drugs Value Market Share Forecast by Application (2021-2025)
Table 78. Pfizer Product Offered
Table 79. Pfizer Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 80. Pfizer Main Business
Table 81. Pfizer Latest Developments
Table 82. Pfizer Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Servier Laboratories Product Offered
Table 84. Servier Laboratories Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 85. Servier Laboratories Main Business
Table 86. Servier Laboratories Latest Developments
Table 87. Servier Laboratories Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. AstraZeneca Product Offered
Table 89. AstraZeneca Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 90. AstraZeneca Main Business
Table 91. AstraZeneca Latest Developments
Table 92. AstraZeneca Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. GlaxoSmithKline Product Offered
Table 94. GlaxoSmithKline Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 95. GlaxoSmithKline Main Business
Table 96. GlaxoSmithKline Latest Developments
Table 97. GlaxoSmithKline Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Merck & Co Product Offered
Table 99. Merck & Co Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 100. Merck & Co Main Business
Table 101. Merck & Co Latest Developments
Table 102. Merck & Co Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Johnson & Johnson Product Offered
Table 104. Johnson & Johnson Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 105. Johnson & Johnson Main Business
Table 106. Johnson & Johnson Latest Developments
Table 107. Johnson & Johnson Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Takeda Pharmaceuticals Product Offered
Table 109. Takeda Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Takeda Pharmaceuticals Main Business
Table 111. Takeda Pharmaceuticals Latest Developments
Table 112. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 113. Eli Lilly Product Offered
Table 114. Eli Lilly Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 115. Eli Lilly Main Business
Table 116. Eli Lilly Latest Developments
Table 117. Eli Lilly Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Novo Nordisk Product Offered
Table 119. Novo Nordisk Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 120. Novo Nordisk Main Business
Table 121. Novo Nordisk Latest Developments
Table 122. Novo Nordisk Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. Sanofi Product Offered
Table 124. Sanofi Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 125. Sanofi Main Business
Table 126. Sanofi Latest Developments
Table 127. Sanofi Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Boehringer Ingelheim Product Offered
Table 129. Boehringer Ingelheim Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 130. Boehringer Ingelheim Main Business
Table 131. Boehringer Ingelheim Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 132. Boehringer Ingelheim Latest Developments
Table 133. Bristol-Myers Squibb Product Offered
Table 134. Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 135. Bristol-Myers Squibb Main Business
Table 136. Bristol-Myers Squibb Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 137. Bristol-Myers Squibb Latest Developments

List of Figures

Figure 1. Picture of Oral Hypoglycemic Drugs
Figure 2. Oral Hypoglycemic Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Oral Hypoglycemic Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Oral Hypoglycemic Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Sulfonylureas (SU)
Figure 7. Product Picture of Double Guanidine
Figure 8. Product Picture of Glucosidase Inhibitor
Figure 9. Product Picture of Insulin Synergist
Figure 10. Global Oral Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Figure 11. Global Oral Hypoglycemic Drugs Value Market Share by Type (2015-2020)
Figure 12. Oral Hypoglycemic Drugs Consumed in Hospital
Figure 13. Global Oral Hypoglycemic Drugs Market: Hospital (2015-2020) (K Units)
Figure 14. Global Oral Hypoglycemic Drugs Market: Hospital (2015-2020) ($ Millions)
Figure 15. Oral Hypoglycemic Drugs Consumed in Clinic
Figure 16. Global Oral Hypoglycemic Drugs Market: Clinic (2015-2020) (K Units)
Figure 17. Global Oral Hypoglycemic Drugs Market: Clinic (2015-2020) ($ Millions)
Figure 18. Oral Hypoglycemic Drugs Consumed in Others
Figure 19. Global Oral Hypoglycemic Drugs Market: Others (2015-2020) (K Units)
Figure 20. Global Oral Hypoglycemic Drugs Market: Others (2015-2020) ($ Millions)
Figure 21. Global Oral Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Figure 22. Global Oral Hypoglycemic Drugs Value Market Share by Application (2015-2020)
Figure 23. Global Oral Hypoglycemic Drugs Sales Market Share by Company in 2017
Figure 24. Global Oral Hypoglycemic Drugs Sales Market Share by Company in 2019
Figure 25. Global Oral Hypoglycemic Drugs Revenue Market Share by Company in 2017
Figure 26. Global Oral Hypoglycemic Drugs Revenue Market Share by Company in 2019
Figure 27. Global Oral Hypoglycemic Drugs Sale Price by Company in 2019
Figure 28. Global Oral Hypoglycemic Drugs Consumption Market Share by Regions 2015-2020
Figure 29. Global Oral Hypoglycemic Drugs Value Market Share by Regions 2015-2020
Figure 30. Americas Oral Hypoglycemic Drugs Consumption 2015-2020 (K Units)
Figure 31. Americas Oral Hypoglycemic Drugs Value 2015-2020 ($ Millions)
Figure 32. APAC Oral Hypoglycemic Drugs Consumption 2015-2020 (K Units)
Figure 33. APAC Oral Hypoglycemic Drugs Value 2015-2020 ($ Millions)
Figure 34. Europe Oral Hypoglycemic Drugs Consumption 2015-2020 (K Units)
Figure 35. Europe Oral Hypoglycemic Drugs Value 2015-2020 ($ Millions)
Figure 36. Middle East & Africa Oral Hypoglycemic Drugs Consumption 2015-2020 (K Units)
Figure 37. Middle East & Africa Oral Hypoglycemic Drugs Value 2015-2020 ($ Millions)
Figure 38. Americas Oral Hypoglycemic Drugs Consumption Market Share by Countries in 2019
Figure 39. Americas Oral Hypoglycemic Drugs Value Market Share by Countries in 2019
Figure 40. Americas Oral Hypoglycemic Drugs Consumption Market Share by Type in 2019
Figure 41. Americas Oral Hypoglycemic Drugs Consumption Market Share by Application in 2019
Figure 42. United States Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 43. United States Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 44. Canada Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 45. Canada Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 46. Mexico Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 47. Mexico Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 48. APAC Oral Hypoglycemic Drugs Consumption Market Share by Countries in 2019
Figure 49. APAC Oral Hypoglycemic Drugs Value Market Share by Regions in 2019
Figure 50. APAC Oral Hypoglycemic Drugs Consumption Market Share by Type in 2019
Figure 51. APAC Oral Hypoglycemic Drugs Consumption Market Share by Application in 2019
Figure 52. China Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 53. China Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 54. Japan Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 55. Japan Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Korea Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 57. Korea Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. Southeast Asia Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 59. Southeast Asia Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 60. India Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 61. India Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 62. Australia Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 63. Australia Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 64. Europe Oral Hypoglycemic Drugs Consumption Market Share by Countries in 2019
Figure 65. Europe Oral Hypoglycemic Drugs Value Market Share by Countries in 2019
Figure 66. Europe Oral Hypoglycemic Drugs Consumption Market Share by Type in 2019
Figure 67. Europe Oral Hypoglycemic Drugs Consumption Market Share by Application in 2019
Figure 68. Germany Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 69. Germany Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 70. France Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 71. France Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. UK Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 73. UK Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. Italy Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 75. Italy Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 76. Russia Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 77. Russia Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 78. Middle East & Africa Oral Hypoglycemic Drugs Consumption Market Share by Countries in 2019
Figure 79. Middle East & Africa Oral Hypoglycemic Drugs Value Market Share by Countries in 2019
Figure 80. Middle East & Africa Oral Hypoglycemic Drugs Consumption Market Share by Type in 2019
Figure 81. Middle East & Africa Oral Hypoglycemic Drugs Consumption Market Share by Application in 2019
Figure 82. Egypt Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 83. Egypt Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 84. South Africa Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 85. South Africa Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. Israel Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 87. Israel Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. Turkey Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 89. Turkey Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 90. GCC Countries Oral Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 91. GCC Countries Oral Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 92. Global Oral Hypoglycemic Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 93. Global Oral Hypoglycemic Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 94. Americas Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 95. Americas Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 96. APAC Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 97. APAC Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 98. Europe Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 99. Europe Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 100. Middle East & Africa Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 101. Middle East & Africa Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 102. United States Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 103. United States Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 104. Canada Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 105. Canada Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 106. Mexico Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 107. Mexico Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 108. Brazil Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 109. Brazil Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 110. China Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 111. China Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 112. Japan Oral Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 113. Japan Oral Hypoglycemic Drugs Value 2021-2025 ($ Millions)
  • Xanthine Oxidase Inhibitor - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "Xanthine Oxidase Inhibitor - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Xanthine Oxidase Inhibitor pipeline landscape is provided, which includes the topic Overview and Xanthine Oxidase Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Xanthine Oxidase Inhibitor commercial assessment and clinical as......
  • Wnt Signaling Pathway Inhibitor - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "Wnt Signaling Pathway Inhibitor - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Wnt Signaling Pathway Inhibitor pipeline landscape is provided, which includes the topic Overview and Wnt Signaling Pathway Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Wnt Signaling Pathway Inhibitor commercial assess......
  • Voltage-Gated Sodium Channel Blockers - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "Voltage-Gated Sodium Channel Blockers - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Voltage-Gated Sodium Channel Blockers pipeline landscape is provided, which includes the topic Overview and Voltage-Gated Sodium Channel Blockers mechanism of action. The assessment part of the report embraces, in-depth Voltage-Gated Sodium Channel Bl......
  • Voltage-Dependent T-Type Calcium Channel Blockers - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "Voltage-Dependent T-Type Calcium Channel Blockers - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Voltage-Dependent T-Type Calcium Channel Blockers pipeline landscape is provided, which includes the topic Overview and Voltage-Dependent T-Type Calcium Channel Blockers mechanism of action. The assessment part of the report embraces, in-d......
  • Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "Voltage-Dependent Calcium Channel Blockers - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Voltage-Dependent Calcium Channel Blockers pipeline landscape is provided, which includes the topic Overview and Voltage-Dependent Calcium Channel Blockers mechanism of action. The assessment part of the report embraces, in-depth Voltage-Dependen......
  • Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist pipeline landscape is provided, which includes the topic Overview and Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist mechanism of action. The assessment part of the rep......
  • Viral RNA Polymerase Inhibitor - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "Viral RNA Polymerase Inhibitor - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Viral RNA Polymerase Inhibitor pipeline landscape is provided, which includes the topic Overview and Viral RNA Polymerase Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Viral RNA Polymerase Inhibitor commercial assessment......
  • VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor pipeline landscape is provided, which includes the topic Overview and VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor mechanism of......
  • Vasopressin V2 Receptor (V2R) Antagonist - Pipeline Insight, 2020
    Published: 03-Jul-2020        Price: US 1500 Onwards        Pages: 60
    Overview "Vasopressin V2 Receptor (V2R) Antagonist - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Vasopressin V2 Receptor (V2R) Antagonist pipeline landscape is provided, which includes the topic Overview and Vasopressin V2 Receptor (V2R) Antagonist mechanism of action. The assessment part of the report embraces, in-depth Vasopressin V2 Recepto......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs